ReviewInternational journal of women's health2026
The 5-Lipoxygenase Pathway in Ovarian Cancer: Mechanisms of Metastasis, Chemoresistance, and Translational Targeting.
Review in International journal of women's health, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Ovarian cancer remains one of the most lethal gynecologic malignancies, characterized by early peritoneal dissemination, extensive microenvironmental remodeling, and frequent emergence of chemoresistance. Beyond genetic alterations, dysregulated lipid mediator signaling represents a regulatory layer that links inflammation, invasion, immune evasion, and cellular stress adaptation. The 5-lipoxygenase (5-LOX, encoded by ALOX5) pathway converts arachidonic acid into bioactive leukotrienes through coordinated activity with 5-LOX-activating protein (FLAP, encoded by ALOX5AP), thereby activating G protein-coupled receptors, including BLT1, BLT2, and cysteinyl leukotriene receptors. This narrative review synthesizes preclinical, translational, and clinical-association evidence for 5-LOX signaling in ovarian cancer. Particular attention is given to BLT2-driven invasion and chemoresistance, hypoxia-induced leukotriene production, macrophage recruitment, ALOX5AP-associated immune suppression, and biomarker-guided therapeutic development. The available evidence supports the 5-LOX axis as a biologically relevant but still clinically immature target. Future development should prioritize compartment-resolved pathway mapping, functional validation in patient-derived models and immune-competent experimental systems, and rational combination strategies rather than unselected monotherapy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.